Global (United States, European Union and China) Liver Cirrhosis
Global (United States, European Union and China) Liver Cirrhosis

Liver Cirrhosis Comprehensive Study by Type (Alcoholic Cirrhosis, Atrophic Cirrhosis, Biliary Cirrhosis, Cardiac Cirrhosis, Cryptogenic Cirrhosis), Application (Hospitals, Specialty Clinics, Others), Treatment (Self-care, Medications {Diuretic, Ammonia Reducer, Beta Blocker, Antibiotics, Antiviral Drug}, Medical procedure {Rubber Band Ligation, Therapeutic Endoscopy, and Transjugular Intrahepatic Portosystemic Shunt}, Surgery {Liver transplantation}), Stages (Stage 1, Stage 2, Stage 3, Stage 4), Tests (Computed Tomography (CT), Ultrasound, Magnetic Resonance Imaging (MRI), Needle Biopsy) Players and Region - Global Market Outlook to 2025

Liver Cirrhosis Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Apr 2020 Edition 231 Pages 163 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Liver Cirrhosis Market Definition
The liver cirrhosis means the condition that causes scar tissue of the liver to replace healthy liver tissue cells, it happens over the period due to the chronic infection or alcohol addiction. It is diagnosed by various radiology tests such as computed tomography (CT), ultrasound, magnetic resonance imaging (MRI), needle biopsy of the liver. A new imaging technique called elastography, which can be performed with ultrasound or MRI, can also diagnosis cirrhosis.

The market study is broken down by Type (Alcoholic Cirrhosis, Atrophic Cirrhosis, Biliary Cirrhosis, Cardiac Cirrhosis and Cryptogenic Cirrhosis), by Application (Hospitals, Specialty Clinics and Others) and major geographies with country level splits.

F. Hoffmann-La Roche AG (Switzerland), Merck & Co., Inc (United States), Abbott Laboratories (United States), Novartis International AG (Switzerland), Bristol Myers Squibb Company (United States), Gilead Sciences, Inc (United States), Conatus Pharmaceuticals (United States), GlaxoSmithKline plc (United Kingdom), Grifols, S.A. (Spain), GWOXI Stem Cell Applied Technology Co., Ltd (China), Hepion Pharmaceuticals (United States), Intercept Pharmaceuticals, Inc. (United States) and Lepu Medical Technology (Beijing) Co., Ltd. (China) are some of the key players that are part of study coverage.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Liver Cirrhosis market by Type, Application and Region.

On the basis of geography, the market of Liver Cirrhosis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Self-care will boost the Liver Cirrhosis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Stages, the sub-segment i.e. Stage 1 will boost the Liver Cirrhosis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Tests, the sub-segment i.e. Computed Tomography (CT) will boost the Liver Cirrhosis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies
On 24th October 2019, Novartis announced the collaboration and license agreement with Pliant Therapeutics to develop and commercialize a preclinical asset, PLN-1474, designed to inhibit the integrin. The agreement also covers a global exclusive license for up to three additional integrin targets. PLN-1474 treats nonalcoholic steatohepatitis (NASH)-related liver fibrosis, which could cause complications, including cirrhosis and liver failure. PLN-1474 demonstrated a significant reduction of fibrosis in live models of human tissue.
On 20th November 2019, Hepion Pharmaceuticals, Inc. announced that CRV431, an anti-fibrotic agent, prevented the development of liver cirrhosis in a highly aggressive, preclinical model of liver disease. In this study, conducted by Physiogenex, S.A.S. (France), rats were administered the hepatotoxic compound, thioacetamide, for nine weeks to induce liver injury and fibrosis, in combination with either CRV431 or vehicle control for the entire study period. Blinded, histopathological analysis of the livers was conducted at the end of the study period.


Market Trend
  • Rising Non-alcoholic Fatty Liver Disease
  • High Risk of Liver Cirrhosis in Young Adults and Women

Market Drivers
  • Growing Prevalence of Obesity and Diabetes Problems in People Across the World
  • Number of Cases with Viral Infections Like Hepatitis B, C, D, and Alcoholism

Opportunities
  • Continuous Research and Development in Liver Cirrhosis Drugs
  • Advancements in Liver Cirrhosis Treatment Imaging Devices

Restraints
  • Lengthy Process Involved in Drug and Treatment Research
  • Complications Involved with Liver Cirrhosis Treatment

Challenges
  • Expensive Liver Transplantation


Key Target Audience
Liver Cirrhosis Equipment Manufacturer, Liver Cirrhosis Treatment Providers, Research and Development Institutes, Potential Investors, Hospitals, Regulatory Bodies and Others

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Alcoholic Cirrhosis
  • Atrophic Cirrhosis
  • Biliary Cirrhosis
  • Cardiac Cirrhosis
  • Cryptogenic Cirrhosis
By Application
  • Hospitals
  • Specialty Clinics
  • Others
By Treatment
  • Self-care
  • Medications {Diuretic, Ammonia Reducer, Beta Blocker, Antibiotics, Antiviral Drug}
  • Medical procedure {Rubber Band Ligation, Therapeutic Endoscopy, and Transjugular Intrahepatic Portosystemic Shunt}
  • Surgery {Liver transplantation}

By Stages
  • Stage 1
  • Stage 2
  • Stage 3
  • Stage 4

By Tests
  • Computed Tomography (CT)
  • Ultrasound
  • Magnetic Resonance Imaging (MRI)
  • Needle Biopsy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Prevalence of Obesity and Diabetes Problems in People Across the World
      • 3.2.2. Number of Cases with Viral Infections Like Hepatitis B, C, D, and Alcoholism
    • 3.3. Market Challenges
      • 3.3.1. Expensive Liver Transplantation
    • 3.4. Market Trends
      • 3.4.1. Rising Non-alcoholic Fatty Liver Disease
      • 3.4.2. High Risk of Liver Cirrhosis in Young Adults and Women
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Liver Cirrhosis, by Type, Application, Treatment, Stages, Tests and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Liver Cirrhosis (Value)
      • 5.2.1. Global Liver Cirrhosis by: Type (Value)
        • 5.2.1.1. Alcoholic Cirrhosis
        • 5.2.1.2. Atrophic Cirrhosis
        • 5.2.1.3. Biliary Cirrhosis
        • 5.2.1.4. Cardiac Cirrhosis
        • 5.2.1.5. Cryptogenic Cirrhosis
      • 5.2.2. Global Liver Cirrhosis by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Specialty Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Liver Cirrhosis by: Treatment (Value)
        • 5.2.3.1. Self-care
        • 5.2.3.2. Medications {Diuretic, Ammonia Reducer, Beta Blocker, Antibiotics, Antiviral Drug}
        • 5.2.3.3. Medical procedure {Rubber Band Ligation, Therapeutic Endoscopy, and Transjugular Intrahepatic Portosystemic Shunt}
        • 5.2.3.4. Surgery {Liver transplantation}
      • 5.2.4. Global Liver Cirrhosis by: Stages (Value)
        • 5.2.4.1. Stage 1
        • 5.2.4.2. Stage 2
        • 5.2.4.3. Stage 3
        • 5.2.4.4. Stage 4
      • 5.2.5. Global Liver Cirrhosis by: Tests (Value)
        • 5.2.5.1. Computed Tomography (CT)
        • 5.2.5.2. Ultrasound
        • 5.2.5.3. Magnetic Resonance Imaging (MRI)
        • 5.2.5.4. Needle Biopsy
      • 5.2.6. Global Liver Cirrhosis Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Liver Cirrhosis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck & Co., Inc (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Abbott Laboratories (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis International AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bristol Myers Squibb Company (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Gilead Sciences, Inc (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Conatus Pharmaceuticals (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GlaxoSmithKline plc (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Grifols, S.A. (Spain)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. GWOXI Stem Cell Applied Technology Co., Ltd (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Hepion Pharmaceuticals (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Intercept Pharmaceuticals, Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Lepu Medical Technology (Beijing) Co., Ltd. (China)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Liver Cirrhosis Sale, by Type, Application, Treatment, Stages, Tests and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Liver Cirrhosis (Value)
      • 7.2.1. Global Liver Cirrhosis by: Type (Value)
        • 7.2.1.1. Alcoholic Cirrhosis
        • 7.2.1.2. Atrophic Cirrhosis
        • 7.2.1.3. Biliary Cirrhosis
        • 7.2.1.4. Cardiac Cirrhosis
        • 7.2.1.5. Cryptogenic Cirrhosis
      • 7.2.2. Global Liver Cirrhosis by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Specialty Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Liver Cirrhosis by: Treatment (Value)
        • 7.2.3.1. Self-care
        • 7.2.3.2. Medications {Diuretic, Ammonia Reducer, Beta Blocker, Antibiotics, Antiviral Drug}
        • 7.2.3.3. Medical procedure {Rubber Band Ligation, Therapeutic Endoscopy, and Transjugular Intrahepatic Portosystemic Shunt}
        • 7.2.3.4. Surgery {Liver transplantation}
      • 7.2.4. Global Liver Cirrhosis by: Stages (Value)
        • 7.2.4.1. Stage 1
        • 7.2.4.2. Stage 2
        • 7.2.4.3. Stage 3
        • 7.2.4.4. Stage 4
      • 7.2.5. Global Liver Cirrhosis by: Tests (Value)
        • 7.2.5.1. Computed Tomography (CT)
        • 7.2.5.2. Ultrasound
        • 7.2.5.3. Magnetic Resonance Imaging (MRI)
        • 7.2.5.4. Needle Biopsy
      • 7.2.6. Global Liver Cirrhosis Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Liver Cirrhosis: by Type(USD Million)
  • Table 2. Liver Cirrhosis Alcoholic Cirrhosis , by Region USD Million (2014-2019)
  • Table 3. Liver Cirrhosis Atrophic Cirrhosis , by Region USD Million (2014-2019)
  • Table 4. Liver Cirrhosis Biliary Cirrhosis , by Region USD Million (2014-2019)
  • Table 5. Liver Cirrhosis Cardiac Cirrhosis , by Region USD Million (2014-2019)
  • Table 6. Liver Cirrhosis Cryptogenic Cirrhosis , by Region USD Million (2014-2019)
  • Table 7. Liver Cirrhosis: by Application(USD Million)
  • Table 8. Liver Cirrhosis Hospitals , by Region USD Million (2014-2019)
  • Table 9. Liver Cirrhosis Specialty Clinics , by Region USD Million (2014-2019)
  • Table 10. Liver Cirrhosis Others , by Region USD Million (2014-2019)
  • Table 11. Liver Cirrhosis: by Treatment(USD Million)
  • Table 12. Liver Cirrhosis Self-care , by Region USD Million (2014-2019)
  • Table 13. Liver Cirrhosis Medications {Diuretic, Ammonia Reducer, Beta Blocker, Antibiotics, Antiviral Drug} , by Region USD Million (2014-2019)
  • Table 14. Liver Cirrhosis Medical procedure {Rubber Band Ligation, Therapeutic Endoscopy, and Transjugular Intrahepatic Portosystemic Shunt} , by Region USD Million (2014-2019)
  • Table 15. Liver Cirrhosis Surgery {Liver transplantation} , by Region USD Million (2014-2019)
  • Table 16. Liver Cirrhosis: by Stages(USD Million)
  • Table 17. Liver Cirrhosis Stage 1 , by Region USD Million (2014-2019)
  • Table 18. Liver Cirrhosis Stage 2 , by Region USD Million (2014-2019)
  • Table 19. Liver Cirrhosis Stage 3 , by Region USD Million (2014-2019)
  • Table 20. Liver Cirrhosis Stage 4 , by Region USD Million (2014-2019)
  • Table 21. Liver Cirrhosis: by Tests(USD Million)
  • Table 22. Liver Cirrhosis Computed Tomography (CT) , by Region USD Million (2014-2019)
  • Table 23. Liver Cirrhosis Ultrasound , by Region USD Million (2014-2019)
  • Table 24. Liver Cirrhosis Magnetic Resonance Imaging (MRI) , by Region USD Million (2014-2019)
  • Table 25. Liver Cirrhosis Needle Biopsy , by Region USD Million (2014-2019)
  • Table 26. South America Liver Cirrhosis, by Country USD Million (2014-2019)
  • Table 27. South America Liver Cirrhosis, by Type USD Million (2014-2019)
  • Table 28. South America Liver Cirrhosis, by Application USD Million (2014-2019)
  • Table 29. South America Liver Cirrhosis, by Treatment USD Million (2014-2019)
  • Table 30. South America Liver Cirrhosis, by Stages USD Million (2014-2019)
  • Table 31. South America Liver Cirrhosis, by Tests USD Million (2014-2019)
  • Table 32. Brazil Liver Cirrhosis, by Type USD Million (2014-2019)
  • Table 33. Brazil Liver Cirrhosis, by Application USD Million (2014-2019)
  • Table 34. Brazil Liver Cirrhosis, by Treatment USD Million (2014-2019)
  • Table 35. Brazil Liver Cirrhosis, by Stages USD Million (2014-2019)
  • Table 36. Brazil Liver Cirrhosis, by Tests USD Million (2014-2019)
  • Table 37. Argentina Liver Cirrhosis, by Type USD Million (2014-2019)
  • Table 38. Argentina Liver Cirrhosis, by Application USD Million (2014-2019)
  • Table 39. Argentina Liver Cirrhosis, by Treatment USD Million (2014-2019)
  • Table 40. Argentina Liver Cirrhosis, by Stages USD Million (2014-2019)
  • Table 41. Argentina Liver Cirrhosis, by Tests USD Million (2014-2019)
  • Table 42. Rest of South America Liver Cirrhosis, by Type USD Million (2014-2019)
  • Table 43. Rest of South America Liver Cirrhosis, by Application USD Million (2014-2019)
  • Table 44. Rest of South America Liver Cirrhosis, by Treatment USD Million (2014-2019)
  • Table 45. Rest of South America Liver Cirrhosis, by Stages USD Million (2014-2019)
  • Table 46. Rest of South America Liver Cirrhosis, by Tests USD Million (2014-2019)
  • Table 47. Asia Pacific Liver Cirrhosis, by Country USD Million (2014-2019)
  • Table 48. Asia Pacific Liver Cirrhosis, by Type USD Million (2014-2019)
  • Table 49. Asia Pacific Liver Cirrhosis, by Application USD Million (2014-2019)
  • Table 50. Asia Pacific Liver Cirrhosis, by Treatment USD Million (2014-2019)
  • Table 51. Asia Pacific Liver Cirrhosis, by Stages USD Million (2014-2019)
  • Table 52. Asia Pacific Liver Cirrhosis, by Tests USD Million (2014-2019)
  • Table 53. China Liver Cirrhosis, by Type USD Million (2014-2019)
  • Table 54. China Liver Cirrhosis, by Application USD Million (2014-2019)
  • Table 55. China Liver Cirrhosis, by Treatment USD Million (2014-2019)
  • Table 56. China Liver Cirrhosis, by Stages USD Million (2014-2019)
  • Table 57. China Liver Cirrhosis, by Tests USD Million (2014-2019)
  • Table 58. Japan Liver Cirrhosis, by Type USD Million (2014-2019)
  • Table 59. Japan Liver Cirrhosis, by Application USD Million (2014-2019)
  • Table 60. Japan Liver Cirrhosis, by Treatment USD Million (2014-2019)
  • Table 61. Japan Liver Cirrhosis, by Stages USD Million (2014-2019)
  • Table 62. Japan Liver Cirrhosis, by Tests USD Million (2014-2019)
  • Table 63. India Liver Cirrhosis, by Type USD Million (2014-2019)
  • Table 64. India Liver Cirrhosis, by Application USD Million (2014-2019)
  • Table 65. India Liver Cirrhosis, by Treatment USD Million (2014-2019)
  • Table 66. India Liver Cirrhosis, by Stages USD Million (2014-2019)
  • Table 67. India Liver Cirrhosis, by Tests USD Million (2014-2019)
  • Table 68. South Korea Liver Cirrhosis, by Type USD Million (2014-2019)
  • Table 69. South Korea Liver Cirrhosis, by Application USD Million (2014-2019)
  • Table 70. South Korea Liver Cirrhosis, by Treatment USD Million (2014-2019)
  • Table 71. South Korea Liver Cirrhosis, by Stages USD Million (2014-2019)
  • Table 72. South Korea Liver Cirrhosis, by Tests USD Million (2014-2019)
  • Table 73. Taiwan Liver Cirrhosis, by Type USD Million (2014-2019)
  • Table 74. Taiwan Liver Cirrhosis, by Application USD Million (2014-2019)
  • Table 75. Taiwan Liver Cirrhosis, by Treatment USD Million (2014-2019)
  • Table 76. Taiwan Liver Cirrhosis, by Stages USD Million (2014-2019)
  • Table 77. Taiwan Liver Cirrhosis, by Tests USD Million (2014-2019)
  • Table 78. Australia Liver Cirrhosis, by Type USD Million (2014-2019)
  • Table 79. Australia Liver Cirrhosis, by Application USD Million (2014-2019)
  • Table 80. Australia Liver Cirrhosis, by Treatment USD Million (2014-2019)
  • Table 81. Australia Liver Cirrhosis, by Stages USD Million (2014-2019)
  • Table 82. Australia Liver Cirrhosis, by Tests USD Million (2014-2019)
  • Table 83. Rest of Asia-Pacific Liver Cirrhosis, by Type USD Million (2014-2019)
  • Table 84. Rest of Asia-Pacific Liver Cirrhosis, by Application USD Million (2014-2019)
  • Table 85. Rest of Asia-Pacific Liver Cirrhosis, by Treatment USD Million (2014-2019)
  • Table 86. Rest of Asia-Pacific Liver Cirrhosis, by Stages USD Million (2014-2019)
  • Table 87. Rest of Asia-Pacific Liver Cirrhosis, by Tests USD Million (2014-2019)
  • Table 88. Europe Liver Cirrhosis, by Country USD Million (2014-2019)
  • Table 89. Europe Liver Cirrhosis, by Type USD Million (2014-2019)
  • Table 90. Europe Liver Cirrhosis, by Application USD Million (2014-2019)
  • Table 91. Europe Liver Cirrhosis, by Treatment USD Million (2014-2019)
  • Table 92. Europe Liver Cirrhosis, by Stages USD Million (2014-2019)
  • Table 93. Europe Liver Cirrhosis, by Tests USD Million (2014-2019)
  • Table 94. Germany Liver Cirrhosis, by Type USD Million (2014-2019)
  • Table 95. Germany Liver Cirrhosis, by Application USD Million (2014-2019)
  • Table 96. Germany Liver Cirrhosis, by Treatment USD Million (2014-2019)
  • Table 97. Germany Liver Cirrhosis, by Stages USD Million (2014-2019)
  • Table 98. Germany Liver Cirrhosis, by Tests USD Million (2014-2019)
  • Table 99. France Liver Cirrhosis, by Type USD Million (2014-2019)
  • Table 100. France Liver Cirrhosis, by Application USD Million (2014-2019)
  • Table 101. France Liver Cirrhosis, by Treatment USD Million (2014-2019)
  • Table 102. France Liver Cirrhosis, by Stages USD Million (2014-2019)
  • Table 103. France Liver Cirrhosis, by Tests USD Million (2014-2019)
  • Table 104. Italy Liver Cirrhosis, by Type USD Million (2014-2019)
  • Table 105. Italy Liver Cirrhosis, by Application USD Million (2014-2019)
  • Table 106. Italy Liver Cirrhosis, by Treatment USD Million (2014-2019)
  • Table 107. Italy Liver Cirrhosis, by Stages USD Million (2014-2019)
  • Table 108. Italy Liver Cirrhosis, by Tests USD Million (2014-2019)
  • Table 109. United Kingdom Liver Cirrhosis, by Type USD Million (2014-2019)
  • Table 110. United Kingdom Liver Cirrhosis, by Application USD Million (2014-2019)
  • Table 111. United Kingdom Liver Cirrhosis, by Treatment USD Million (2014-2019)
  • Table 112. United Kingdom Liver Cirrhosis, by Stages USD Million (2014-2019)
  • Table 113. United Kingdom Liver Cirrhosis, by Tests USD Million (2014-2019)
  • Table 114. Netherlands Liver Cirrhosis, by Type USD Million (2014-2019)
  • Table 115. Netherlands Liver Cirrhosis, by Application USD Million (2014-2019)
  • Table 116. Netherlands Liver Cirrhosis, by Treatment USD Million (2014-2019)
  • Table 117. Netherlands Liver Cirrhosis, by Stages USD Million (2014-2019)
  • Table 118. Netherlands Liver Cirrhosis, by Tests USD Million (2014-2019)
  • Table 119. Rest of Europe Liver Cirrhosis, by Type USD Million (2014-2019)
  • Table 120. Rest of Europe Liver Cirrhosis, by Application USD Million (2014-2019)
  • Table 121. Rest of Europe Liver Cirrhosis, by Treatment USD Million (2014-2019)
  • Table 122. Rest of Europe Liver Cirrhosis, by Stages USD Million (2014-2019)
  • Table 123. Rest of Europe Liver Cirrhosis, by Tests USD Million (2014-2019)
  • Table 124. MEA Liver Cirrhosis, by Country USD Million (2014-2019)
  • Table 125. MEA Liver Cirrhosis, by Type USD Million (2014-2019)
  • Table 126. MEA Liver Cirrhosis, by Application USD Million (2014-2019)
  • Table 127. MEA Liver Cirrhosis, by Treatment USD Million (2014-2019)
  • Table 128. MEA Liver Cirrhosis, by Stages USD Million (2014-2019)
  • Table 129. MEA Liver Cirrhosis, by Tests USD Million (2014-2019)
  • Table 130. Middle East Liver Cirrhosis, by Type USD Million (2014-2019)
  • Table 131. Middle East Liver Cirrhosis, by Application USD Million (2014-2019)
  • Table 132. Middle East Liver Cirrhosis, by Treatment USD Million (2014-2019)
  • Table 133. Middle East Liver Cirrhosis, by Stages USD Million (2014-2019)
  • Table 134. Middle East Liver Cirrhosis, by Tests USD Million (2014-2019)
  • Table 135. Africa Liver Cirrhosis, by Type USD Million (2014-2019)
  • Table 136. Africa Liver Cirrhosis, by Application USD Million (2014-2019)
  • Table 137. Africa Liver Cirrhosis, by Treatment USD Million (2014-2019)
  • Table 138. Africa Liver Cirrhosis, by Stages USD Million (2014-2019)
  • Table 139. Africa Liver Cirrhosis, by Tests USD Million (2014-2019)
  • Table 140. North America Liver Cirrhosis, by Country USD Million (2014-2019)
  • Table 141. North America Liver Cirrhosis, by Type USD Million (2014-2019)
  • Table 142. North America Liver Cirrhosis, by Application USD Million (2014-2019)
  • Table 143. North America Liver Cirrhosis, by Treatment USD Million (2014-2019)
  • Table 144. North America Liver Cirrhosis, by Stages USD Million (2014-2019)
  • Table 145. North America Liver Cirrhosis, by Tests USD Million (2014-2019)
  • Table 146. United States Liver Cirrhosis, by Type USD Million (2014-2019)
  • Table 147. United States Liver Cirrhosis, by Application USD Million (2014-2019)
  • Table 148. United States Liver Cirrhosis, by Treatment USD Million (2014-2019)
  • Table 149. United States Liver Cirrhosis, by Stages USD Million (2014-2019)
  • Table 150. United States Liver Cirrhosis, by Tests USD Million (2014-2019)
  • Table 151. Canada Liver Cirrhosis, by Type USD Million (2014-2019)
  • Table 152. Canada Liver Cirrhosis, by Application USD Million (2014-2019)
  • Table 153. Canada Liver Cirrhosis, by Treatment USD Million (2014-2019)
  • Table 154. Canada Liver Cirrhosis, by Stages USD Million (2014-2019)
  • Table 155. Canada Liver Cirrhosis, by Tests USD Million (2014-2019)
  • Table 156. Mexico Liver Cirrhosis, by Type USD Million (2014-2019)
  • Table 157. Mexico Liver Cirrhosis, by Application USD Million (2014-2019)
  • Table 158. Mexico Liver Cirrhosis, by Treatment USD Million (2014-2019)
  • Table 159. Mexico Liver Cirrhosis, by Stages USD Million (2014-2019)
  • Table 160. Mexico Liver Cirrhosis, by Tests USD Million (2014-2019)
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Company Basic Information, Sales Area and Its Competitors
  • Table 173. Company Basic Information, Sales Area and Its Competitors
  • Table 174. Liver Cirrhosis: by Type(USD Million)
  • Table 175. Liver Cirrhosis Alcoholic Cirrhosis , by Region USD Million (2020-2025)
  • Table 176. Liver Cirrhosis Atrophic Cirrhosis , by Region USD Million (2020-2025)
  • Table 177. Liver Cirrhosis Biliary Cirrhosis , by Region USD Million (2020-2025)
  • Table 178. Liver Cirrhosis Cardiac Cirrhosis , by Region USD Million (2020-2025)
  • Table 179. Liver Cirrhosis Cryptogenic Cirrhosis , by Region USD Million (2020-2025)
  • Table 180. Liver Cirrhosis: by Application(USD Million)
  • Table 181. Liver Cirrhosis Hospitals , by Region USD Million (2020-2025)
  • Table 182. Liver Cirrhosis Specialty Clinics , by Region USD Million (2020-2025)
  • Table 183. Liver Cirrhosis Others , by Region USD Million (2020-2025)
  • Table 184. Liver Cirrhosis: by Treatment(USD Million)
  • Table 185. Liver Cirrhosis Self-care , by Region USD Million (2020-2025)
  • Table 186. Liver Cirrhosis Medications {Diuretic, Ammonia Reducer, Beta Blocker, Antibiotics, Antiviral Drug} , by Region USD Million (2020-2025)
  • Table 187. Liver Cirrhosis Medical procedure {Rubber Band Ligation, Therapeutic Endoscopy, and Transjugular Intrahepatic Portosystemic Shunt} , by Region USD Million (2020-2025)
  • Table 188. Liver Cirrhosis Surgery {Liver transplantation} , by Region USD Million (2020-2025)
  • Table 189. Liver Cirrhosis: by Stages(USD Million)
  • Table 190. Liver Cirrhosis Stage 1 , by Region USD Million (2020-2025)
  • Table 191. Liver Cirrhosis Stage 2 , by Region USD Million (2020-2025)
  • Table 192. Liver Cirrhosis Stage 3 , by Region USD Million (2020-2025)
  • Table 193. Liver Cirrhosis Stage 4 , by Region USD Million (2020-2025)
  • Table 194. Liver Cirrhosis: by Tests(USD Million)
  • Table 195. Liver Cirrhosis Computed Tomography (CT) , by Region USD Million (2020-2025)
  • Table 196. Liver Cirrhosis Ultrasound , by Region USD Million (2020-2025)
  • Table 197. Liver Cirrhosis Magnetic Resonance Imaging (MRI) , by Region USD Million (2020-2025)
  • Table 198. Liver Cirrhosis Needle Biopsy , by Region USD Million (2020-2025)
  • Table 199. South America Liver Cirrhosis, by Country USD Million (2020-2025)
  • Table 200. South America Liver Cirrhosis, by Type USD Million (2020-2025)
  • Table 201. South America Liver Cirrhosis, by Application USD Million (2020-2025)
  • Table 202. South America Liver Cirrhosis, by Treatment USD Million (2020-2025)
  • Table 203. South America Liver Cirrhosis, by Stages USD Million (2020-2025)
  • Table 204. South America Liver Cirrhosis, by Tests USD Million (2020-2025)
  • Table 205. Brazil Liver Cirrhosis, by Type USD Million (2020-2025)
  • Table 206. Brazil Liver Cirrhosis, by Application USD Million (2020-2025)
  • Table 207. Brazil Liver Cirrhosis, by Treatment USD Million (2020-2025)
  • Table 208. Brazil Liver Cirrhosis, by Stages USD Million (2020-2025)
  • Table 209. Brazil Liver Cirrhosis, by Tests USD Million (2020-2025)
  • Table 210. Argentina Liver Cirrhosis, by Type USD Million (2020-2025)
  • Table 211. Argentina Liver Cirrhosis, by Application USD Million (2020-2025)
  • Table 212. Argentina Liver Cirrhosis, by Treatment USD Million (2020-2025)
  • Table 213. Argentina Liver Cirrhosis, by Stages USD Million (2020-2025)
  • Table 214. Argentina Liver Cirrhosis, by Tests USD Million (2020-2025)
  • Table 215. Rest of South America Liver Cirrhosis, by Type USD Million (2020-2025)
  • Table 216. Rest of South America Liver Cirrhosis, by Application USD Million (2020-2025)
  • Table 217. Rest of South America Liver Cirrhosis, by Treatment USD Million (2020-2025)
  • Table 218. Rest of South America Liver Cirrhosis, by Stages USD Million (2020-2025)
  • Table 219. Rest of South America Liver Cirrhosis, by Tests USD Million (2020-2025)
  • Table 220. Asia Pacific Liver Cirrhosis, by Country USD Million (2020-2025)
  • Table 221. Asia Pacific Liver Cirrhosis, by Type USD Million (2020-2025)
  • Table 222. Asia Pacific Liver Cirrhosis, by Application USD Million (2020-2025)
  • Table 223. Asia Pacific Liver Cirrhosis, by Treatment USD Million (2020-2025)
  • Table 224. Asia Pacific Liver Cirrhosis, by Stages USD Million (2020-2025)
  • Table 225. Asia Pacific Liver Cirrhosis, by Tests USD Million (2020-2025)
  • Table 226. China Liver Cirrhosis, by Type USD Million (2020-2025)
  • Table 227. China Liver Cirrhosis, by Application USD Million (2020-2025)
  • Table 228. China Liver Cirrhosis, by Treatment USD Million (2020-2025)
  • Table 229. China Liver Cirrhosis, by Stages USD Million (2020-2025)
  • Table 230. China Liver Cirrhosis, by Tests USD Million (2020-2025)
  • Table 231. Japan Liver Cirrhosis, by Type USD Million (2020-2025)
  • Table 232. Japan Liver Cirrhosis, by Application USD Million (2020-2025)
  • Table 233. Japan Liver Cirrhosis, by Treatment USD Million (2020-2025)
  • Table 234. Japan Liver Cirrhosis, by Stages USD Million (2020-2025)
  • Table 235. Japan Liver Cirrhosis, by Tests USD Million (2020-2025)
  • Table 236. India Liver Cirrhosis, by Type USD Million (2020-2025)
  • Table 237. India Liver Cirrhosis, by Application USD Million (2020-2025)
  • Table 238. India Liver Cirrhosis, by Treatment USD Million (2020-2025)
  • Table 239. India Liver Cirrhosis, by Stages USD Million (2020-2025)
  • Table 240. India Liver Cirrhosis, by Tests USD Million (2020-2025)
  • Table 241. South Korea Liver Cirrhosis, by Type USD Million (2020-2025)
  • Table 242. South Korea Liver Cirrhosis, by Application USD Million (2020-2025)
  • Table 243. South Korea Liver Cirrhosis, by Treatment USD Million (2020-2025)
  • Table 244. South Korea Liver Cirrhosis, by Stages USD Million (2020-2025)
  • Table 245. South Korea Liver Cirrhosis, by Tests USD Million (2020-2025)
  • Table 246. Taiwan Liver Cirrhosis, by Type USD Million (2020-2025)
  • Table 247. Taiwan Liver Cirrhosis, by Application USD Million (2020-2025)
  • Table 248. Taiwan Liver Cirrhosis, by Treatment USD Million (2020-2025)
  • Table 249. Taiwan Liver Cirrhosis, by Stages USD Million (2020-2025)
  • Table 250. Taiwan Liver Cirrhosis, by Tests USD Million (2020-2025)
  • Table 251. Australia Liver Cirrhosis, by Type USD Million (2020-2025)
  • Table 252. Australia Liver Cirrhosis, by Application USD Million (2020-2025)
  • Table 253. Australia Liver Cirrhosis, by Treatment USD Million (2020-2025)
  • Table 254. Australia Liver Cirrhosis, by Stages USD Million (2020-2025)
  • Table 255. Australia Liver Cirrhosis, by Tests USD Million (2020-2025)
  • Table 256. Rest of Asia-Pacific Liver Cirrhosis, by Type USD Million (2020-2025)
  • Table 257. Rest of Asia-Pacific Liver Cirrhosis, by Application USD Million (2020-2025)
  • Table 258. Rest of Asia-Pacific Liver Cirrhosis, by Treatment USD Million (2020-2025)
  • Table 259. Rest of Asia-Pacific Liver Cirrhosis, by Stages USD Million (2020-2025)
  • Table 260. Rest of Asia-Pacific Liver Cirrhosis, by Tests USD Million (2020-2025)
  • Table 261. Europe Liver Cirrhosis, by Country USD Million (2020-2025)
  • Table 262. Europe Liver Cirrhosis, by Type USD Million (2020-2025)
  • Table 263. Europe Liver Cirrhosis, by Application USD Million (2020-2025)
  • Table 264. Europe Liver Cirrhosis, by Treatment USD Million (2020-2025)
  • Table 265. Europe Liver Cirrhosis, by Stages USD Million (2020-2025)
  • Table 266. Europe Liver Cirrhosis, by Tests USD Million (2020-2025)
  • Table 267. Germany Liver Cirrhosis, by Type USD Million (2020-2025)
  • Table 268. Germany Liver Cirrhosis, by Application USD Million (2020-2025)
  • Table 269. Germany Liver Cirrhosis, by Treatment USD Million (2020-2025)
  • Table 270. Germany Liver Cirrhosis, by Stages USD Million (2020-2025)
  • Table 271. Germany Liver Cirrhosis, by Tests USD Million (2020-2025)
  • Table 272. France Liver Cirrhosis, by Type USD Million (2020-2025)
  • Table 273. France Liver Cirrhosis, by Application USD Million (2020-2025)
  • Table 274. France Liver Cirrhosis, by Treatment USD Million (2020-2025)
  • Table 275. France Liver Cirrhosis, by Stages USD Million (2020-2025)
  • Table 276. France Liver Cirrhosis, by Tests USD Million (2020-2025)
  • Table 277. Italy Liver Cirrhosis, by Type USD Million (2020-2025)
  • Table 278. Italy Liver Cirrhosis, by Application USD Million (2020-2025)
  • Table 279. Italy Liver Cirrhosis, by Treatment USD Million (2020-2025)
  • Table 280. Italy Liver Cirrhosis, by Stages USD Million (2020-2025)
  • Table 281. Italy Liver Cirrhosis, by Tests USD Million (2020-2025)
  • Table 282. United Kingdom Liver Cirrhosis, by Type USD Million (2020-2025)
  • Table 283. United Kingdom Liver Cirrhosis, by Application USD Million (2020-2025)
  • Table 284. United Kingdom Liver Cirrhosis, by Treatment USD Million (2020-2025)
  • Table 285. United Kingdom Liver Cirrhosis, by Stages USD Million (2020-2025)
  • Table 286. United Kingdom Liver Cirrhosis, by Tests USD Million (2020-2025)
  • Table 287. Netherlands Liver Cirrhosis, by Type USD Million (2020-2025)
  • Table 288. Netherlands Liver Cirrhosis, by Application USD Million (2020-2025)
  • Table 289. Netherlands Liver Cirrhosis, by Treatment USD Million (2020-2025)
  • Table 290. Netherlands Liver Cirrhosis, by Stages USD Million (2020-2025)
  • Table 291. Netherlands Liver Cirrhosis, by Tests USD Million (2020-2025)
  • Table 292. Rest of Europe Liver Cirrhosis, by Type USD Million (2020-2025)
  • Table 293. Rest of Europe Liver Cirrhosis, by Application USD Million (2020-2025)
  • Table 294. Rest of Europe Liver Cirrhosis, by Treatment USD Million (2020-2025)
  • Table 295. Rest of Europe Liver Cirrhosis, by Stages USD Million (2020-2025)
  • Table 296. Rest of Europe Liver Cirrhosis, by Tests USD Million (2020-2025)
  • Table 297. MEA Liver Cirrhosis, by Country USD Million (2020-2025)
  • Table 298. MEA Liver Cirrhosis, by Type USD Million (2020-2025)
  • Table 299. MEA Liver Cirrhosis, by Application USD Million (2020-2025)
  • Table 300. MEA Liver Cirrhosis, by Treatment USD Million (2020-2025)
  • Table 301. MEA Liver Cirrhosis, by Stages USD Million (2020-2025)
  • Table 302. MEA Liver Cirrhosis, by Tests USD Million (2020-2025)
  • Table 303. Middle East Liver Cirrhosis, by Type USD Million (2020-2025)
  • Table 304. Middle East Liver Cirrhosis, by Application USD Million (2020-2025)
  • Table 305. Middle East Liver Cirrhosis, by Treatment USD Million (2020-2025)
  • Table 306. Middle East Liver Cirrhosis, by Stages USD Million (2020-2025)
  • Table 307. Middle East Liver Cirrhosis, by Tests USD Million (2020-2025)
  • Table 308. Africa Liver Cirrhosis, by Type USD Million (2020-2025)
  • Table 309. Africa Liver Cirrhosis, by Application USD Million (2020-2025)
  • Table 310. Africa Liver Cirrhosis, by Treatment USD Million (2020-2025)
  • Table 311. Africa Liver Cirrhosis, by Stages USD Million (2020-2025)
  • Table 312. Africa Liver Cirrhosis, by Tests USD Million (2020-2025)
  • Table 313. North America Liver Cirrhosis, by Country USD Million (2020-2025)
  • Table 314. North America Liver Cirrhosis, by Type USD Million (2020-2025)
  • Table 315. North America Liver Cirrhosis, by Application USD Million (2020-2025)
  • Table 316. North America Liver Cirrhosis, by Treatment USD Million (2020-2025)
  • Table 317. North America Liver Cirrhosis, by Stages USD Million (2020-2025)
  • Table 318. North America Liver Cirrhosis, by Tests USD Million (2020-2025)
  • Table 319. United States Liver Cirrhosis, by Type USD Million (2020-2025)
  • Table 320. United States Liver Cirrhosis, by Application USD Million (2020-2025)
  • Table 321. United States Liver Cirrhosis, by Treatment USD Million (2020-2025)
  • Table 322. United States Liver Cirrhosis, by Stages USD Million (2020-2025)
  • Table 323. United States Liver Cirrhosis, by Tests USD Million (2020-2025)
  • Table 324. Canada Liver Cirrhosis, by Type USD Million (2020-2025)
  • Table 325. Canada Liver Cirrhosis, by Application USD Million (2020-2025)
  • Table 326. Canada Liver Cirrhosis, by Treatment USD Million (2020-2025)
  • Table 327. Canada Liver Cirrhosis, by Stages USD Million (2020-2025)
  • Table 328. Canada Liver Cirrhosis, by Tests USD Million (2020-2025)
  • Table 329. Mexico Liver Cirrhosis, by Type USD Million (2020-2025)
  • Table 330. Mexico Liver Cirrhosis, by Application USD Million (2020-2025)
  • Table 331. Mexico Liver Cirrhosis, by Treatment USD Million (2020-2025)
  • Table 332. Mexico Liver Cirrhosis, by Stages USD Million (2020-2025)
  • Table 333. Mexico Liver Cirrhosis, by Tests USD Million (2020-2025)
  • Table 334. Research Programs/Design for This Report
  • Table 335. Key Data Information from Secondary Sources
  • Table 336. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Liver Cirrhosis: by Type USD Million (2014-2019)
  • Figure 5. Global Liver Cirrhosis: by Application USD Million (2014-2019)
  • Figure 6. Global Liver Cirrhosis: by Treatment USD Million (2014-2019)
  • Figure 7. Global Liver Cirrhosis: by Stages USD Million (2014-2019)
  • Figure 8. Global Liver Cirrhosis: by Tests USD Million (2014-2019)
  • Figure 9. South America Liver Cirrhosis Share (%), by Country
  • Figure 10. Asia Pacific Liver Cirrhosis Share (%), by Country
  • Figure 11. Europe Liver Cirrhosis Share (%), by Country
  • Figure 12. MEA Liver Cirrhosis Share (%), by Country
  • Figure 13. North America Liver Cirrhosis Share (%), by Country
  • Figure 14. Global Liver Cirrhosis share by Players 2019 (%)
  • Figure 15. Global Liver Cirrhosis share by Players (Top 3) 2019(%)
  • Figure 16. Global Liver Cirrhosis share by Players (Top 5) 2019(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2019
  • Figure 20. Merck & Co., Inc (United States) Revenue, Net Income and Gross profit
  • Figure 21. Merck & Co., Inc (United States) Revenue: by Geography 2019
  • Figure 22. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 23. Abbott Laboratories (United States) Revenue: by Geography 2019
  • Figure 24. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Novartis International AG (Switzerland) Revenue: by Geography 2019
  • Figure 26. Bristol Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 27. Bristol Myers Squibb Company (United States) Revenue: by Geography 2019
  • Figure 28. Gilead Sciences, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 29. Gilead Sciences, Inc (United States) Revenue: by Geography 2019
  • Figure 30. Conatus Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 31. Conatus Pharmaceuticals (United States) Revenue: by Geography 2019
  • Figure 32. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2019
  • Figure 34. Grifols, S.A. (Spain) Revenue, Net Income and Gross profit
  • Figure 35. Grifols, S.A. (Spain) Revenue: by Geography 2019
  • Figure 36. GWOXI Stem Cell Applied Technology Co., Ltd (China) Revenue, Net Income and Gross profit
  • Figure 37. GWOXI Stem Cell Applied Technology Co., Ltd (China) Revenue: by Geography 2019
  • Figure 38. Hepion Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 39. Hepion Pharmaceuticals (United States) Revenue: by Geography 2019
  • Figure 40. Intercept Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 41. Intercept Pharmaceuticals, Inc. (United States) Revenue: by Geography 2019
  • Figure 42. Lepu Medical Technology (Beijing) Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 43. Lepu Medical Technology (Beijing) Co., Ltd. (China) Revenue: by Geography 2019
  • Figure 44. Global Liver Cirrhosis: by Type USD Million (2020-2025)
  • Figure 45. Global Liver Cirrhosis: by Application USD Million (2020-2025)
  • Figure 46. Global Liver Cirrhosis: by Treatment USD Million (2020-2025)
  • Figure 47. Global Liver Cirrhosis: by Stages USD Million (2020-2025)
  • Figure 48. Global Liver Cirrhosis: by Tests USD Million (2020-2025)
  • Figure 49. South America Liver Cirrhosis Share (%), by Country
  • Figure 50. Asia Pacific Liver Cirrhosis Share (%), by Country
  • Figure 51. Europe Liver Cirrhosis Share (%), by Country
  • Figure 52. MEA Liver Cirrhosis Share (%), by Country
  • Figure 53. North America Liver Cirrhosis Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • F. Hoffmann-La Roche AG (Switzerland)
  • Merck & Co., Inc (United States)
  • Abbott Laboratories (United States)
  • Novartis International AG (Switzerland)
  • Bristol Myers Squibb Company (United States)
  • Gilead Sciences, Inc (United States)
  • Conatus Pharmaceuticals (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • Grifols, S.A. (Spain)
  • GWOXI Stem Cell Applied Technology Co., Ltd (China)
  • Hepion Pharmaceuticals (United States)
  • Intercept Pharmaceuticals, Inc. (United States)
  • Lepu Medical Technology (Beijing) Co., Ltd. (China)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation